Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VitaminBlock

Financiado

Cerrado

Development of antibacterial compounds that block essential transport function

Development of new antibiotics is crucial in future since antibiotic resistance is a rapidly growing problem, which severely threatens our ability to combat infectious diseases. Despite the numerous efforts by International Organi... ver más

31/03/2020

RIJKSUNIVERSITEIT...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

RIJKSUNIVERSITEIT GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-03-31

ERC-2018-PoC: ERC Proof of Concept Grant

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

RIJKSUNIVERSITEIT GRONINGEN

150.00K€ | Lider

ZIGOR CORPORACION

243.60K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PDC2021-121544-I00 DISEÑO DE UNA NUEVA CLASE DE ANTIMICROBIANOS CONTRA INFECCIO... 133K€ Cerrado

PID2019-105126RB-I00 ULTRAESTRUCTURA Y ALCANCE BIOTECNOLOGICO DE LOS MODULOS DE U... 145K€ Cerrado

ENABLE European Gram Negative Antibacterial Engine 101M€ Cerrado

DIVINOCELL Exploiting Gram negative cell division targets in the test t... 8M€ Cerrado

PCI2022-134981-2 OPTIMISATION OF BI-THERAPY INHIBITION OF STAPHYLOCOCCUS AURE... 180K€ Cerrado

Duración del proyecto: 21 meses Fecha Inicio: 2018-06-25
Fecha Fin: 2020-03-31

Líder del proyecto

RIJKSUNIVERSITEIT GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Development of new antibiotics is crucial in future since antibiotic resistance is a rapidly growing problem, which severely threatens our ability to combat infectious diseases. Despite the numerous efforts by International Organisations and Governments, Pharmaceutical companies are reluctant to carry out the costly drug development, as the returns are uncertain and evolving drug resistance weakens their business case further. New solutions are thus called for. We have obtained fundamental insight in the mechanisms and proteins, which mediate uptake of multiple B-type vitamins that are indispensable for bacterial growth. The proteins are the only route for vitamin acquisition in many notorious pathogens such as Staphylococcus aureus and Streptococcus pneumoniae, against which novel antibiotics are urgently needed. Based on our breakthrough crystal structures, we have designed and synthesized molecules that allosterically inhibit the uptake of multiple vitamins. This has led to the discovery of several compounds having potential as antibiotic medicines. What is exciting, our approach enables to target specific pathogens, without affecting many beneficial strains, thereby being effective without causing adverse drug events, which is a major advantage compared to the traditional antibiotics. In the Proof of Concept project, we aim to explore the potential of the compounds for drug development and test them thoroughly, for obtaining important proof for potential partners and investors. In addition, we will carry out pre-commercialisation studies aiming at perfecting the commercialisation strategy, protecting the IP ad well as strengthen the network for the best possible commercialisation outcome. Given the technological and pre-commercial proof of concept will be successful, we are expecting our approach to raise a lot of interest in Pharmaceutical industry, racing to find new ways to tackle the antimicrobial resistance.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores